论文部分内容阅读
目的评价荷丹片与瑞舒伐他汀合用治疗高脂血症患者的疗效和安全性。方法 62例原发混合型高血脂症患者,随机分为2组,联合组31例,每天服用10mg瑞舒伐他汀和荷丹片每次2片,每天3次;单药组31例,服用瑞舒伐他汀10mg。2组均治疗6个月,治疗前检查血脂、肝肾功能、肌酸磷酸激酶(CK)、血常规及心电图和X线胸片检查;3,6个月时复查血脂、肝肾功能、CK,观察调脂疗效和不良反应。结果治疗后2组各项血脂指标与治疗前比较,除单药组HDL-C外,其余各指标均有显著改善(P<0.05),其中联合组总胆固醇(TC)从(6.78±0.36)mmol/L降至(4.10±0.34)mmol/L(P<0.05),低密度脂蛋白胆固醇(LDL-C)从(4.40±0.22)mmol/L降至(2.60±0.25)mmol/L(P<0.05),甘油三酯(TG)从(3.43±0.34)mmol/L降至(1.52±0.24)mmol/L(P<0.05),高密度脂蛋白胆固醇(HDL-C)从(0.78±0.05)mmol/L升至(1.52±0.03)mmol/L(P<0.05)。其中TG下降、HDL-C升高较单药组明显(P均<0.05)。结论荷丹片与瑞舒伐他汀合用降TG和升HDL-C的作用,优于瑞舒伐他汀单药治疗,且具有良好的安全性。
Objective To evaluate the efficacy and safety of hollymine and rosuvastatin in the treatment of hyperlipidemia. Methods Sixty-two patients with primary hypercholesterolemia were randomly divided into two groups. The combination group consisted of 31 patients. Each group took 10 mg of rosuvastatin and lovastatin tablets twice daily for 3 times a day. In the single drug group, 31 patients were given Rosuvastatin 10mg. 2 groups were treated for 6 months, before treatment, blood lipids, liver and kidney function, creatine phosphokinase (CK), blood and ECG and chest X-ray examination; 3,6 months review of blood lipids, liver and kidney function, CK , Observe the effect of lipid-lowering and adverse reactions. Results After treatment, the levels of total cholesterol (TC) increased from (6.78 ± 0.36) vs those of HDL-C alone (P <0.05) LDL-C decreased from (4.40 ± 0.22) mmol / L to (2.60 ± 0.25) mmol / L (P <0.05) (P <0.05). The level of triglyceride decreased from (3.43 ± 0.34) mmol / L to (1.52 ± 0.24) mmol / L and the level of HDL-C decreased from (0.78 ± 0.05 ) mmol / L to (1.52 ± 0.03) mmol / L (P <0.05). Among them, TG decreased and HDL-C increased significantly (P <0.05). Conclusions The combination of Houdan tablets and rosuvastatin is better than rosuvastatin monotherapy in combination with lowering TG and increasing HDL-C, and has good safety.